Over our tenure as the statistical editors of *AJRCCM* and *AnnalsATS*, we have observed recurrent methodological issues and reporting practices in submitted manuscripts that invariably lead to unfavorable reviews by statistical reviewers, content reviewers, and editorial board members. In an effort to help authors improve both the statistical rigor and clinical impact of their manuscripts, we have developed this document to both combine our suggestions and centralize resources and references that authors can use to avoid common pitfalls and improve reporting quality.

Clearly State the Aims of the Study in the Introduction
=======================================================

To assess whether the selected methods are appropriate for a study, the goals and specific hypotheses being tested must be clearly stated. This is often not the case. We recommend that authors use a PICO (population, intervention, comparator, outcome) ([@bib1]) template or extension ([@bib2]) (tailored PICO templates are available for most study designs) to develop clear study aims and research questions.

Follow Relevant Reporting Guidelines and Provide Details Regarding Analytic Decisions
=====================================================================================

Providing a full accounting of the study design, data collection, and data analysis can seem like an overwhelming task in any study, particularly within allowed word count limits. Thankfully, although a study *question* might be novel, the study *design* is usually not, and authors should take advantage of the many available guidelines and checklists that have been developed to detail what information should be reported for a given study design. To promote awareness, in [Table 1](#tbl1){ref-type="table"}, we list the guidelines for many common study designs, all of which are available from the EQUATOR (Enhancing the Quality and Transparency of Health Research) Network ([www.equator-network.org/](http://www.equator-network.org/)). The easiest way for authors to enhance the quality of their manuscript is to include all of the items and elements listed in the appropriate reporting guideline and accompanying checklist for their specific study design. These guidelines also provide a natural structure and sequence for authors to follow when writing their manuscript, because reporting elements are usually separated by each section of a manuscript (e.g., methods, results). For more detailed guidance on manuscript development in pulmonary and critical care medicine, we recommend the article by Viglianti and colleagues ([@bib3]).

###### 

Reporting Guidelines for Common Study Designs

  Study Type                                                   Reporting Guidelines
  ----------------------------------------------------------- ----------------------
  Randomized trial                                                   CONSORT
  Observational study[\*](#tblfn1){ref-type="table-fn"}               STROBE
  Systematic review                                                   PRISMA
  Study protocol                                                 SPIRIT, PRISMA-P
  Prediction model study[^†^](#tblfn2){ref-type="table-fn"}           TRIPOD
  Case report                                                          CARE
  Clinical practice guideline                                      AGREE, RIGHT
  Qualitative research                                             SRQR, COREQ
  Animal preclinical study                                            ARRIVE
  Quality improvement study                                           SQUIRE
  Economic evaluation                                                 CHEERS

*Definition of abbreviations*: AGREE = Appraisal of Guidelines, Research and Evaluation; ARRIVE = Animal Research: Reporting of *In Vivo* Experiments; CARE = Case Report guidelines ([www.care-statement.org](http://www.care-statement.org/)); CHEERS = Consolidated Health Economic Evaluation Reporting Standards; CONSORT = Consolidated Standards of Reporting Trials; COREQ = Consolidated Criteria for Reporting Qualitative Studies; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PRISMA-P = Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols; RIGHT = Reporting Items for Practice Guidelines in Healthcare; SPIRIT = Standard Protocol Items: Recommendations for Interventional Trials; SQUIRE = Standards for Quality Improvement Reporting Excellence; SRQR = Standards for Reporting Qualitative Research; STROBE = Strengthening the Reporting of Observational Studies in Epidemiology; TRIPOD = Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis.

At the time of publication, a total of 424 reporting guidelines were available at the EQUATOR (Enhancing the Quality and Transparency of Health Research) Network website ([www.equator-network.org](http://www.equator-network.org/)), covering almost all potential research activities. Adapted by permission from Reference [@bib20].

*See also* recent guidance for observational causal inference studies in pulmonary, critical care, and sleep medicine ([@bib9]).

*See also* recent guidance for prediction model studies in pulmonary, critical care, and sleep medicine ([@bib11]).

We are also strong proponents of the SAMPL (Statistical Analyses and Methods in the Published Literature) guidelines ([@bib4]). The SAMPL guidelines are applicable to almost any statistical analysis or numeric value that authors may conduct or report, respectively. We also recommend that authors explore the statistical analysis and reporting guidance provided by Assel and colleagues ([@bib5]) and the *Annals of Internal Medicine* ([@bib6]), both of which are open access.

Though these are mostly requested in the aforementioned study-specific guidelines, we also wish to highlight a few persistently problematic or omitted areas of manuscripts ([Table 2](#tbl2){ref-type="table"}). For all studies, authors must report any missing data and then discuss and justify their approach for handling missing data (e.g., imputation method and variables used). In observational studies in which researchers are seeking to describe a relationship or association between an exposure and an outcome, we want to see a rationale for all included confounder variables and a discussion (and potentially an analysis \[[@bib7], [@bib8]\]) of the potential impact of missing confounders. For additional guidance, we recommend the causal inference resource by Lederer and colleagues ([@bib9]) and that authors follow the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement ([@bib10]) and checklist ([Table 1](#tbl1){ref-type="table"}). Finally, the development, validation, and updating of prediction models is a popular pursuit, but one wrought with many challenges in execution and description. For additional guidance, we recommend the resource by Leisman and colleagues ([@bib11]) that builds heavily on the TRIPOD (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis) statement ([@bib12]) and checklist ([Table 1](#tbl1){ref-type="table"}).

###### 

Key Elements That Should Be Reported in Research Manuscripts

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  • Indicate that the appropriate reporting guideline ([Table 1](#tbl1){ref-type="table"}) was followed. We encourage authors to include the accompanying checklist, if there is one for the guidelines they are using, in the supplementary material.
  • Include a reference number for the ethics board or animal care and use approval. This is the legal authority for the work and allows traceability for the use of data and human samples.
  • Report information regarding preregistration of clinical trials and systematic reviews. Any changes or deviations from original and published protocols, particularly for trials, should be reported. We check [www.clinicaltrials.gov](http://www.clinicaltrials.gov), PROSPERO, and other repositories. We are increasingly confirming that results of clinical trials have been submitted to [www.clinicaltrials.gov](http://www.clinicaltrials.gov) or EudraCT within the required time frame (i.e., within 1 yr of study completion for [www.clinicaltrials.gov](http://www.clinicaltrials.gov)).
  • Report when and where the study was completed.
  • Report the potentially eligible and final sample sizes, together with study inclusion and exclusion criteria, ideally in a flowchart. Also explain the rationale for choosing the inclusion and exclusion criteria.
  • Include a detailed description and rationale for the statistical analyses. This description should include the testing of assumptions associated with the selected statistical model(s), how missing data were handled, any sensitivity analyses, and information regarding the statistical software and packages used by the authors.
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Definition of abbreviations*: EudraCT = European Union Drug Regulating Authorities Clinical Trials Database; PROSPERO = international prospective register of systematic reviews in health and social care.

Because some journals (e.g., *AJRCCM* and *AnnalsATS*) favor a brief description of the methods in the main manuscript, authors must achieve a balance between what is reported in the main manuscript text and the online supplement. We suggest that authors focus on key data and analytic details in the main text while also providing more detailed text in the unlimited space provided by the online supplement.

Present Results in a Manner That Allows Readers to Easily Follow and Assess the Analysis
========================================================================================

The structure of the results section and content of tables and figures (including those in the supplement) should follow a natural progression and sequentially present the analysis that has been outlined in the methods. As suggested above, the study-specific guidelines available at the EQUATOR Network website ([Table 1](#tbl1){ref-type="table"}) provide a natural structure for reporting results. For example, the STROBE checklist would structure the results of an observational cohort or cross-sectional study to begin with a summary of participant eligibility and data availability, followed by descriptive characteristics, a summary of the outcome or summary measures, the primary statistical analysis, and concluding with additional (e.g., sensitivity, exploratory) analyses ([@bib10]). In addition, the SAMPL guidelines include specific guidance for reporting descriptive statistics, rates, risks, ratios, correlations, regression models, time-to-event analyses, and Bayesian analyses, among many others. If a study includes adjustment for confounding, we prefer that authors show both unadjusted and adjusted results. We also recommend that authors report results on both the absolute (e.g., risk or mean difference) and relative scales (e.g., risk ratio), when relevant. Predicted values (e.g., adjusted probabilities or marginal means) can also greatly aid the interpretation of an analysis and are easily derived in all popular statistical packages ([@bib13]).

Address the Study's Limitations Head On
=======================================

There is not a study design, data source, or statistical method that does not have limitations. We are always impressed when authors present a transparent, balanced, and well-articulated reporting of methods, results, limitations, and potential biases. Conversely, papers that omit, trivialize, or downplay major limitations give a negative impression, and authors will likely be asked to defend these positions empirically.

Acknowledge That Even In-Vogue Methods Have Assumptions and Limitations
=======================================================================

We are always excited to review papers that include a thoughtful rationale for the chosen analytic methods (particularly if it educates the readership) and that tests the assumptions of those methods. Sensitivity analyses that demonstrate the robustness of the results by contrasting them with results from alternative analytic strategies or alternative outcome definitions or inclusion criteria are also encouraged.

In our experience, we have seen an increase in manuscripts that use propensity scores and machine-learning methods without the aforementioned qualities. For this reason, we recommend that authors who elect to use propensity scores address at least five specific items; to assist authors, we have added informative citations to the first three recommendations:1.Explain why propensity score methods are preferable to traditional covariate adjustment ([@bib14]--[@bib17]).2.Explain why a specific propensity score approach (e.g., matching or inverse probability weighting) was used, because the effect estimates have varying interpretations ([@bib16]--[@bib18]).3.Assess the positivity assumption ([@bib19]).4.Address limitations intrinsic to all observational studies (e.g., measurement error, confounding by indication, unmeasured confounding).5.Avoid language suggesting that by performing a propensity score analysis, the observational results are akin to results from a randomized trial.

When authors use machine-learning methods, we expect the same standards in reporting and the use of reporting guidelines ([Table 1](#tbl1){ref-type="table"}). For example, the TRIPOD guidelines should be followed if machine-learning methods are used to develop a prediction model. We also challenge authors to justify their methodological choices on the basis of their study question. We are especially wary of manuscripts in which newer methods are used without a clear rationale, those that lack a discussion of the assumptions and limitations of the selected method(s), and those that cannot describe the impact of changes in covariates (i.e., black-box algorithms).

Final Thoughts
==============

Our goal in writing this editorial was to help authors strengthen the presentation of methods and results in research manuscripts. If we had to select only one of these suggestions, it would be that authors find the appropriate guidelines for reporting a particular type of study ([Table 1](#tbl1){ref-type="table"}) and ensure that their manuscript includes all of the requested information. The goals of those who create reporting guidelines and checklists are ones that we share: We want manuscripts to describe the different steps of the analysis with sufficient precision to support the *1*) reproducibility of the analysis if one had access to the same data and *2*) evaluation of the analytic methods and decisions. Relative to the effort required to design a study, collect data, and analyze results, we believe that the limited time required to optimize transparent and thorough reporting of a study is minor, promotes good science, and is likely to create a favorable impression on those reviewing your paper.
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